Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Partners With Ajou University Hospital to Expand Real-World Data Network in Asia

NEW YORK – Syapse said on Tuesday that it was partnering with Ajou University Hospital in South Korea to use real-world evidence to accelerate precision medicine and improve outcomes for cancer patients.

Syapse, a company that makes software to support precision oncology care, is building an international network, called the Learning Health Network, which allows healthcare providers to share real-world clinical, molecular, treatment, and outcomes data in order to improve understanding of the efficacy and safety of cancer treatments in patients who are clinically and molecularly similar. Syapse and its network partners are hoping to use this data to support clinical decisions and deliver precision cancer care. Data collected within the network can also be used to support R&D projects, clinical trial matching, regulatory filings, and post-approval monitoring.

Cancer centers and hospitals collaborating with Syapse will use its secure platform to share de-identified data that is standardized and normalized across the network and that complies with all applicable federal and state data privacy protection regulations.

This latest collaboration brings Ajou University Hospital into the Learning Health Network and expands the network's reach in South Korea.

"Syapse's health system network has been expanding as we add new partners who are focused on leveraging the value of real-world data to rapidly enhance precision medicine and improve patient outcomes," Syapse CEO Ken Tarkoff said in a statement. "We are committed to providing the most updated medical information and insights to Ajou's healthcare providers across its 10 cancer care centers, and look forward to continued growth in South Korea."

Syapse inked an agreement with another South Korean hospital, Seoul National University Hospital, in 2018. 

In May, Syapse raised $30 million in new equity investments to support its collaborations and its application of precision medicine in guiding real-world outcomes.